New Initiatives - Under Development

  • Call for ideas to accelerate time to diagnosis
  • TDP 43 Imaging Challenge grant with ALSA Partnership
  • Sensors for ALS
  • Understanding resistance to ALS (studies in identical twins who do not develop ALS; or carriers of gene causing mutations who do not develop ALS)
  • Call for grants to use existing biosamples/clinical data to accelerate diagnosis and disease related biomarkers

Call for Phase II Proposals

ALS ACT and the Northeast ALS Consortium (NEALS) are pleased to announce a call for phase II clinical trial applications for novel, high-potential treatments in Amyotrophic Lateral Sclerosis. The call for clinical study proposals is open to academic-industry partnerships, including pharmaceutical, biotherapeutic/biotechnology companies, academic members of the NEALS and ALS scientists worldwide. The deadline for Letter of Intent submissions is November 30, 2015.
More information
Letter of intent

A Program Of

Advisory Board

  • Leandro P. Rizzuto
  • Peter N. Foss
  • Merit  Cudkowicz, MD
  • Denis  Rizzuto
  • Stanley H. Appel, MD
  • Robert  Brown, D.Phil., MD
  • Tom  Gentile
  • Clive  Svendsen, PhD
  • Richard  Ellenbogen, MD
  • Randy  Fishman
  • Edward J. Rapp